Oral eradication therapy for melioidosis: Important but not without risks.

Area of Science:

• Tropical medicine
• Infectious diseases
• Pharmacology

Background:

• Melioidosis is a serious bacterial infection prevalent in tropical regions.
• Oral eradication therapy, typically with trimethoprim-sulfamethoxazole, is crucial for preventing relapse.
• High-dose, long-duration trimethoprim-sulfamethoxazole regimens are commonly used.

Purpose of the Study:

• To quantify the adverse effects associated with oral eradication therapy for melioidosis.
• To assess the impact of these adverse effects on treatment completion and management.

Main Methods:

• Retrospective cohort study design.
• Inclusion of patients with first-episode, culture-confirmed melioidosis.
• Data collection on adverse events from oral eradication therapy.

Main Results:

• Trimethoprim-sulfamethoxazole was prescribed to 95.8% of patients receiving oral eradication therapy.
• 30.0% of patients on trimethoprim-sulfamethoxazole experienced adverse effects.
• Adverse effects frequently led to treatment cessation, modification, or dose reduction.

Conclusions:

• High rates of adverse effects from oral trimethoprim-sulfamethoxazole are observed in melioidosis patients in Northern Australia.
• These side effects often necessitate changes in antibiotic therapy or dose adjustments.
• Emphasis on the importance of prior intensive intravenous therapy and weight-based dosing for oral eradication.